CABP


Also found in: Medical.
AcronymDefinition
CABPCommunity-Acquired Bacterial Pneumonia
CaBPCalcium Binding Protein
CABPCanadian Alliance of British Pensioners (Toronto, Canada)
CABPCameron Ashley Building Products, Inc. (Dallas, TX)
CABPCoalition Air Battle Planning
CABPCarotid Artery Blood Pressure
CABPCertificate of the Arab Board of Pediatrics
References in periodicals archive ?
CABP is an acute bacterial infection of the pulmonary parenchyma that is:
A procedure plagued by complication rates, figures show that post-surgery complications have been reported in as high as 15 to 25 per cent of cases of CABP.
circa 1898] in Folder 22: Recommendations for Charles Austin Beard, DC 10, CABP.
In fact, nearly one-quarter of surveyed physicians indicate prescribing ceftaroline for CABP due to MRSA, and about 10 percent have used the drug for NP in the past 12 months.
In conjunction, the sponsors engaged in clinical trials for these ABSSSI, CABP and HABP conditions are currently using different methodologies to assess the primary endpoint as there is no qualified PRO instrument, added the company.
The Pharmacor advisory service entitled Community-Acquired Bacterial Pneumonia finds that the CABP antibiotic market will experience modest growth over the next decade, increasing from approximately $1 billion in 2011 to more than $1.
Although many strains of the primary CABP pathogen, Streptococcus pneumoniae, are resistant to currently-approved macrolides, this class of antibiotic remains among the most commonly prescribed antibacterial drugs for CABP in both the hospital and community settings.
Rib-X announced in September that the FDA designated delafloxacin as a QIDP for ABSSSI and CABP.
Net proceeds may be used by the company to fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the US; the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in acute bacterial skin and skin structure infections (ABSSSI); for the chronic oral treatment of refractory infections in bones and joints; and working capital as well as general corporate and administrative expenses.
The community-acquired bacterial pneumonia (CABP) market is highly crowded and genericized; nevertheless, it has important unmet needs for new therapies that are active against key drug-resistant pathogens and that can demonstrate efficacy in the moderate to severe CABP population.
Net proceeds may be used by the company to: fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the US; research and development activities; the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in acute bacterial skin and skin structure infections (ABSSSI); for the chronic oral treatment of refractory infections in bones and joints; working capital; and general corporate and administrative expenses.
Previously, the US FDA has designated the company's omadacycline as a Qualified Infectious Disease Product (QIDP) for treating ABSSSI, CABP, cUTI.